EA200971096A1 - Терапевтические композиции и их применение - Google Patents
Терапевтические композиции и их применениеInfo
- Publication number
- EA200971096A1 EA200971096A1 EA200971096A EA200971096A EA200971096A1 EA 200971096 A1 EA200971096 A1 EA 200971096A1 EA 200971096 A EA200971096 A EA 200971096A EA 200971096 A EA200971096 A EA 200971096A EA 200971096 A1 EA200971096 A1 EA 200971096A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- application
- therapeutic compositions
- pharmaceutically acceptable
- acceptable salt
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 229960004525 lopinavir Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94732507P | 2007-06-29 | 2007-06-29 | |
| PCT/US2008/068351 WO2009006203A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200971096A1 true EA200971096A1 (ru) | 2010-08-30 |
Family
ID=39817166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200971096A EA200971096A1 (ru) | 2007-06-29 | 2008-06-26 | Терапевтические композиции и их применение |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20090093482A1 (enExample) |
| EP (1) | EP2167089A1 (enExample) |
| JP (3) | JP5547067B2 (enExample) |
| KR (1) | KR20100028656A (enExample) |
| CN (2) | CN103356622A (enExample) |
| AP (1) | AP2490A (enExample) |
| AR (1) | AR067184A1 (enExample) |
| AU (1) | AU2008270634B2 (enExample) |
| BR (1) | BRPI0813955A2 (enExample) |
| CA (1) | CA2691736A1 (enExample) |
| CO (1) | CO6251236A2 (enExample) |
| EA (1) | EA200971096A1 (enExample) |
| EC (1) | ECSP109889A (enExample) |
| IL (1) | IL202745A0 (enExample) |
| MX (1) | MX2009013828A (enExample) |
| NZ (1) | NZ582089A (enExample) |
| SG (1) | SG182228A1 (enExample) |
| TW (1) | TW200916103A (enExample) |
| UA (1) | UA103881C2 (enExample) |
| WO (1) | WO2009006203A1 (enExample) |
| ZA (1) | ZA201000468B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101524165B1 (ko) * | 2005-12-30 | 2015-06-01 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 |
| SI2049506T2 (sl) | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| HRP20090213B1 (hr) | 2006-09-12 | 2016-12-02 | Gilead Sciences, Inc. | Postupak i međuprodukti u pripravi inhibitora integraze |
| ES2779826T3 (es) * | 2007-02-23 | 2020-08-20 | Gilead Sciences Inc | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| CN101686972B (zh) * | 2007-06-29 | 2013-08-14 | 吉里德科学公司 | 治疗用组合物和方法 |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX342377B (es) | 2008-05-02 | 2016-09-27 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| CN102917695A (zh) * | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
| US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2013130766A1 (en) * | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
| AU2013296289B2 (en) | 2012-08-03 | 2017-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| SI3067358T1 (sl) | 2012-12-21 | 2019-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
| AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| BRPI0306214B1 (pt) * | 2002-11-20 | 2017-08-08 | Japan Tobacco Inc. | 4-oxoquinoline compound and use of this as a hiv integrase inhibitor |
| US20060111933A1 (en) * | 2003-10-09 | 2006-05-25 | Steven Wheeler | Adaptive medical decision support system |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP3287130A1 (en) * | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| KR101524165B1 (ko) * | 2005-12-30 | 2015-06-01 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| SI2049506T2 (sl) * | 2006-07-07 | 2024-07-31 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
| HRP20090213B1 (hr) * | 2006-09-12 | 2016-12-02 | Gilead Sciences, Inc. | Postupak i međuprodukti u pripravi inhibitora integraze |
| CN101686972B (zh) * | 2007-06-29 | 2013-08-14 | 吉里德科学公司 | 治疗用组合物和方法 |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX342377B (es) * | 2008-05-02 | 2016-09-27 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 CN CN2013101948825A patent/CN103356622A/zh active Pending
- 2008-06-26 BR BRPI0813955A patent/BRPI0813955A2/pt not_active IP Right Cessation
- 2008-06-26 MX MX2009013828A patent/MX2009013828A/es not_active Application Discontinuation
- 2008-06-26 EA EA200971096A patent/EA200971096A1/ru unknown
- 2008-06-26 US US12/147,220 patent/US20090093482A1/en not_active Abandoned
- 2008-06-26 SG SG2012046926A patent/SG182228A1/en unknown
- 2008-06-26 EP EP20080781024 patent/EP2167089A1/en not_active Withdrawn
- 2008-06-26 US US12/666,995 patent/US20110009411A1/en not_active Abandoned
- 2008-06-26 AP AP2009005083A patent/AP2490A/xx active
- 2008-06-26 CA CA002691736A patent/CA2691736A1/en not_active Abandoned
- 2008-06-26 WO PCT/US2008/068351 patent/WO2009006203A1/en not_active Ceased
- 2008-06-26 KR KR1020107001984A patent/KR20100028656A/ko not_active Ceased
- 2008-06-26 AU AU2008270634A patent/AU2008270634B2/en not_active Ceased
- 2008-06-26 CN CN200880022821A patent/CN101743004A/zh active Pending
- 2008-06-26 AR ARP080102760A patent/AR067184A1/es not_active Application Discontinuation
- 2008-06-26 NZ NZ582089A patent/NZ582089A/xx not_active IP Right Cessation
- 2008-06-26 JP JP2010515115A patent/JP5547067B2/ja not_active Expired - Fee Related
- 2008-06-26 TW TW097123981A patent/TW200916103A/zh unknown
- 2008-06-26 UA UAA200913904A patent/UA103881C2/ru unknown
-
2009
- 2009-12-15 IL IL202745A patent/IL202745A0/en unknown
- 2009-12-21 CO CO09146050A patent/CO6251236A2/es not_active Application Discontinuation
-
2010
- 2010-01-21 EC EC2010009889A patent/ECSP109889A/es unknown
- 2010-01-21 ZA ZA2010/00468A patent/ZA201000468B/en unknown
-
2013
- 2013-07-08 JP JP2013142320A patent/JP5769762B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,790 patent/US20140343062A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094705A patent/JP2015143277A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,070 patent/US20170136000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356622A (zh) | 2013-10-23 |
| NZ582089A (en) | 2013-01-25 |
| JP5769762B2 (ja) | 2015-08-26 |
| AU2008270634B2 (en) | 2014-01-16 |
| BRPI0813955A2 (pt) | 2017-05-09 |
| EP2167089A1 (en) | 2010-03-31 |
| KR20100028656A (ko) | 2010-03-12 |
| AP2009005083A0 (en) | 2009-12-31 |
| ECSP109889A (es) | 2010-03-31 |
| JP5547067B2 (ja) | 2014-07-09 |
| TW200916103A (en) | 2009-04-16 |
| JP2013199494A (ja) | 2013-10-03 |
| ZA201000468B (en) | 2011-06-29 |
| JP2015143277A (ja) | 2015-08-06 |
| IL202745A0 (en) | 2010-06-30 |
| AP2490A (en) | 2012-10-04 |
| US20170136000A1 (en) | 2017-05-18 |
| CO6251236A2 (es) | 2011-02-21 |
| AU2008270634A1 (en) | 2009-01-08 |
| UA103881C2 (ru) | 2013-12-10 |
| JP2010532373A (ja) | 2010-10-07 |
| US20110009411A1 (en) | 2011-01-13 |
| SG182228A1 (en) | 2012-07-30 |
| AR067184A1 (es) | 2009-09-30 |
| US20140343062A1 (en) | 2014-11-20 |
| CN101743004A (zh) | 2010-06-16 |
| US20090093482A1 (en) | 2009-04-09 |
| CA2691736A1 (en) | 2009-01-08 |
| MX2009013828A (es) | 2010-03-10 |
| WO2009006203A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200971096A1 (ru) | Терапевтические композиции и их применение | |
| EA200971093A1 (ru) | Терапевтические композиции и их применение | |
| EA201291301A1 (ru) | Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич | |
| EA201100613A1 (ru) | Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций | |
| EA201391395A1 (ru) | Терапевтические соединения | |
| EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| EA201070786A1 (ru) | Бензофуропиримидиноны | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| EA201290416A1 (ru) | Новые спиропиперидиновые соединения | |
| EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
| EA201200098A1 (ru) | Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия |